Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Monogram Orthopaedics Inc ( (MGRM) ) has provided an announcement.
On September 30, 2025, Monogram Technologies Inc. held a special meeting of its common stockholders to vote on a merger proposal with Zimmer Biomet Holdings, Inc. The merger involves Monogram becoming a wholly-owned subsidiary of Zimmer Biomet. The merger proposal was approved by approximately 63.95% of the voting shares. The company expects to finalize the merger in the second half of 2025, pending satisfaction of customary closing conditions.
The most recent analyst rating on (MGRM) stock is a Buy with a $10.80 price target. To see the full list of analyst forecasts on Monogram Orthopaedics Inc stock, see the MGRM Stock Forecast page.
Spark’s Take on MGRM Stock
According to Spark, TipRanks’ AI Analyst, MGRM is a Neutral.
Monogram Orthopaedics Inc. shows promise due to significant technological advancements and recent regulatory clearances, which are key drivers for potential growth. However, financial instability, regulatory uncertainties, and ongoing profitability challenges weigh heavily on the overall score. The stock’s upward momentum is a positive indicator, but valuation metrics remain weak due to negative earnings and lack of dividends.
To see Spark’s full report on MGRM stock, click here.
More about Monogram Orthopaedics Inc
Average Trading Volume: 382,898
Technical Sentiment Signal: Buy
For detailed information about MGRM stock, go to TipRanks’ Stock Analysis page.